In this episode, Linda R. Duska, MD, MPH; Robert L. Coleman, MD, FACOG, FACS; and Leslie Randall, MD, MAS, answer questions from an audience of healthcare professionals on topics related to the management of patients with endometrial and ovarian cancer including:  

• Adding bevacizumab to chemotherapy in frontline endometrial cancer
• Lenvatinib and pembrolizumab in MSI-H/dMMR endometrial cancer
• PARP inhibitor maintenance in ovarian cancer
• Bevacizumab with or without PARP inhibitors in ovarian cancer

Presenters:

Linda R. Duska, MD, MPH
Lawrence W. Penniston MD Family Professor in Women’s Oncology Research
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

Robert L. Coleman, MD, FACOG, FACS
Gynecologic Oncologist and Chief Scientific Officer
US Oncology, US Oncology Research
The Woodlands, Texas

Leslie Randall, MD, MAS  
Diane Harris Wright Professor and Director
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Massey Cancer Center
Virginia Commonwealth University
Richmond, Virginia

Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/3e6pZCM 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.